



Attorney Docket No.: 6423.404-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Hansen et al.

Serial No.: 10/602,838

Group Art Unit: 1651

Filed: June 24, 2003

Examiner: To be assigned

For: Liquid Composition of Factor VII Polypeptides

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References (10)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on October 1, 2003

Dolly Kapadia  
(name of person mailing paper)

Dolly Kapadia  
(signature of person mailing paper)



Attorney Docket No.: 6423.404-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Hansen et al.

Application No.: 10/602,838

Group Art Unit: To be assigned

Filed: June 24, 2003

Examiner: To be assigned

For: Liquid Composition of Factor VII Polypeptides

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. U.S. Patent no. 4,297,344
2. U.S. Patent no. 5,770,700
3. U.S. Patent Application Publication no. US 2001/0031721 A1
4. WO 94/26286 A1

5. WO 97/47651 A1
6. WO 97/19687 A1
7. Laegemiddel Kataloget, pages 893-894 (2000) (translation)
8. Manning et al., Pharmaceutical Research, Vol. 6, No. 11, pages 903-918 (1989)
9. Cleland et al., Critical Reviews in Therapeutic Drug Carrier Systems, Vol. 10, No. 4, pages 307-377 (1993)
10. Wang et al., Journal of Parenteral Science and Technology, Vol. 42, pages S2-S26 (1988)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Date: October 1, 2003


Respectfully submitted,



Reza Green, Reg. No. 38,475  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

23650

PATENT TRADEMARK OFFICE



|   |                                     |                              |
|---|-------------------------------------|------------------------------|
| U.S. DEPARTMENT OF COMMERCE<br>PATENT AND TRADEMARK OFFICE<br><br>INFORMATION DISCLOSURE<br>STATEMENT BY APPLICANT<br><br>(Use several sheets if necessary) | Atty. Docket No. <b>6423.404-US</b> | Serial No. <b>10/602,838</b> |
|   | Applicant <b>Hansen et al.</b>      |                              |
|   | Filing Date <b>June 24, 2003</b>    | Group <b>To be assigned</b>  |

## U.S. PATENT DOCUMENTS

| EXAMINER<br>INITIAL | DOCUMENT<br>NUMBER    | DATE     | NAME           | CLASS | SUBCLASS | FILING DATE<br>IF APPROPRIATE |
|---------------------|-----------------------|----------|----------------|-------|----------|-------------------------------|
|                     | 4,297,344             | 10/27/81 | Schwinn et al. | 424   | 101      |                               |
|                     | 5,770,700             | 6/23/98  | Webb et al.    | 530   | 383      |                               |
|                     | US 2001/0031721<br>A1 | 10/18/01 | Webb et al.    | 514   | 2        |                               |
|                     |                       |          |                |       |          |                               |
|                     |                       |          |                |       |          |                               |

## FOREIGN PATENT DOCUMENTS

|  | DOCUMENT<br>NUMBER | DATE     | COUNTRY | CLASS | SUBCLASS | TRANSLATION |    |
|--|--------------------|----------|---------|-------|----------|-------------|----|
|  |                    |          |         |       |          | YES         | NO |
|  | WO 94/26286 A1     | 11/24/94 | PCT     |       |          |             |    |
|  | WO 97/47651 A1     | 12/18/97 | PCT     |       |          |             |    |
|  | WO 97/19687        | 6/5/97   | PCT     |       |          |             |    |
|  |                    |          |         |       |          |             |    |
|  |                    |          |         |       |          |             |    |

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

|          |                 |   |
|----------|-----------------|---|
|          |                 | Laegemiddel Kataloget, pages 893-894 (2000) (translation)   |
|          |                 |   |
|          |                 | Manning et al., Pharmaceutical Research, Vol. 6, No. 11, pages 903-918 (1989)                                 |
|          |                 |   |
|          |                 | Cleland et al., Critical Reviews in Therapeutic Drug Carrier Systems,<br>Vol. 10, No. 4, pages 307-377 (1993) |
|          |                 |   |
|          |                 | Wang et al., Journal of Parenteral Science and Technology, Vol. 42,<br>pages S2-S26 (1988)                    |
|          |                 |   |
|          |                 |   |
|          |                 |   |
| EXAMINER | DATE CONSIDERED |   |

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.